Lavi Shahar, Lavi Ronit, McConnell Joseph P, Lerman Lilach O, Lerman Amir
Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA.
Mol Diagn Ther. 2007;11(4):219-26. doi: 10.1007/BF03256243.
The role of inflammation in atherosclerosis continues to emerge. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), a novel plasma biomarker, circulates in the blood bound mainly to low-density lipoprotein (LDL) and promotes vascular inflammation. Several epidemiological studies have shown that circulating levels of Lp-PLA(2) are an independent risk factor for cardiovascular events. Recent studies demonstrate that Lp-PLA(2) is also associated with endothelial dysfunction and early atherosclerosis. This review provides an overview of these studies, suggests plausible mechanisms for the association between endothelial dysfunction and Lp-PLA(2), and highlights future potential therapies.
炎症在动脉粥样硬化中的作用仍在不断显现。脂蛋白相关磷脂酶A2(Lp-PLA2)是一种新型血浆生物标志物,主要与低密度脂蛋白(LDL)结合在血液中循环,并促进血管炎症。多项流行病学研究表明,Lp-PLA2的循环水平是心血管事件的独立危险因素。最近的研究表明,Lp-PLA2还与内皮功能障碍和早期动脉粥样硬化有关。本文综述了这些研究,提出了内皮功能障碍与Lp-PLA2之间关联的可能机制,并强调了未来潜在的治疗方法。